Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia...
Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia (CLL).
SGN-40, a genetically engineered monoclonal antibody, is already being studied for multiple myeloma and non-Hodgkin’s lymphoma in other early trials.
The Bothell company also said SGN-40 received “orphan drug” designation for CLL from the Food and Drug Administration. The designation, for treatment of relatively rare diseases, means Seattle Genetics will have seven years of market exclusivity if the drug is approved.
The company’s stock lost 8 cents, or 1.6 percent, to close at $4.93 Tuesday. It fell 3 more cents in after-hours trading.
Most Read Stories
- Man shot at UW no racist, friends insist, despite shooter’s claim
- We need real solutions to vehicle campers | Editorial
- Crowd comparison: Inauguration Friday and women's march Saturday
- Record Seattle crowd asserts women’s rights: 'Trump has galvanized everybody' WATCH
- Will Seahawks keep Luke Willson? That's among questions facing tight end position in offseason